Nautilus Biotechnology, Inc. (NAUT) Form 8-K — Oct 26, 2026
Nautilus Biotechnology reported Q3 2026 results with revenue of $0.2 million, driven mainly by grant revenue from the Michael J. Fox Foundation and early-access service revenue. Net loss widened to $15.6 million from $13.6 million a year ago as operating expenses rose 10% to $16.9 million. The company ended the quarter with $114.3 million in cash, cash equivalents and investments.
Key figures
- Revenue
- 234000
- Total Assets
- 148924000
- Cash Position
- 114300000
- Arpa h seeds funding up to
- 6000000
- Operating expenses q3 2026
- 16947000
- Operating expenses yoy change
- +$1.5M (10%) increase vs $15.5M
- Instrument availability target
- mid-2027
- Assays planned through mid 2028
- 20
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.